March 3, 2024

Latest Commentary

News and Political Commentary

Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial

2 min read

Article content

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023

KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive patients with previously untreated metastatic uveal melanoma

Article content

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md, 21 October 2023) Immunocore Holdings plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious diseases and autoimmune conditions, today announces that the three-year overall survival (OS) data from the KIMMTRAK (tebentafusp-tebn) Phase 3 trial in previously untreated HLA-A*02:01 positive patients with metastatic uveal melanoma has been published in The New England Journal of Medicine, and presented as a late breaking abstract in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2023.

Advertisement 2

GlobeNewswire

2023-10-21 08:45:05

All news and articles are copyrighted to the respective authors and/or News Broadcasters. VIXC.Com is an independent Online News Aggregator


Read more from original source here…

About Author

Leave a Reply

Copyright © All rights reserved. | Newsphere by AF themes.